Treatment

The lung scarring that occurs in interstitial lung disease can't be reversed, and treatment will not always be effective in stopping the ultimate progression of the disease. Some treatments may improve symptoms temporarily or slow the disease's progress. Others help improve quality of life.

Because many of the different types of scarring disorders have no approved or proven therapies, clinical studies may be an option to receive an experimental treatment.

Medications

Intense research to identify treatment options for specific types of interstitial lung disease is ongoing. Based on currently available, scientific evidence, however, your doctor may recommend:

  • Corticosteroid medications. Many people diagnosed with interstitial lung diseases are initially treated with a corticosteroid (prednisone), sometimes in combination with other drugs that suppress the immune system. Depending on the cause of the interstitial lung disease, this combination may slow or even stabilize disease progression.
  • Medications that slow the progression of idiopathic pulmonary fibrosis. The medications pirfenidone (Esbriet) and nintedanib (Ofev) may slow the rate of disease progression. Treatment-related side effects may be significant. Talk through the pros and cons of these medications with your doctor.
  • Medications that reduce stomach acid. Gastroesophageal reflux disease (GERD) affects the majority of people with idiopathic pulmonary fibrosis and is associated with worsening lung damage. If you have symptoms of acid reflux, your doctor may prescribe GERD therapies that reduce stomach acid, including H-2-receptor antagonists or proton pump inhibitors such as lansoprazole (Prevacid 24HR), omeprazole (Prilosec OTC) and pantoprazole (protonix).

Oxygen therapy

Using oxygen can't stop lung damage, but it can:

  • Make breathing and exercise easier
  • Prevent or lessen complications from low blood oxygen levels
  • Reduce blood pressure in the right side of your heart
  • Improve your sleep and sense of well-being

You're most likely to receive oxygen when you sleep or exercise, although some people may use it round-the-clock.

Pulmonary rehabilitation

The aim of pulmonary rehabilitation is not only to improve daily functioning but also to help people with intersitial lung disease live full, satisfying lives. To that end, pulmonary rehabilitation programs focus on:

  • Physical exercise, to improve your endurance
  • Breathing techniques that improve lung efficiency
  • Emotional support
  • Nutritional counseling

Surgery

Lung transplantation may be an option of last resort for some people with severe interstitial lung disease who haven't benefited from other treatment options.

July 21, 2017
References
  1. Raghu G, et al. An official ATS/ERS/JRS/ALAT clinical practice guideline: Treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline. American Journal of Respiratory and Critical Care Medicine. 2015;192:e3.
  2. Goldman L, et al., eds. Interstitial lung disease. In: Goldman-Cecil Medicine. 25th ed. Philadelphia, Pa.: Saunders Elsevier; 2016. http://www.clinicalkey.com. Accessed May 17, 2017.
  3. Mason RJ, et al. Patholody: Malignant and interstitial lung diseases. In: Murray and Nadel's Textbook of Respiratory Medicine. 6th ed. Philadelphia, Pa.: Saunders Elsevier; 2016. http://www.clinicalkey.com. Accessed May 17, 2017.
  4. Ferri FF. Interstitial lung disease. In: Ferri's Clinical Advisor 2017. Philadelphia, Pa.: Elsevier; 2017. https://www.clinicalkey.com. Accessed May 17, 2017.
  5. Martinez FJ, et al. The diagnosis of idiopathic pulmonary fibrosis: current and future approaches. The Lancet Respiratory Medicine. 2017;5:61.
  6. Han Q, et al. Diagnostic yield and postoperative mortality associated with surgical lung biopsy for evaluation of interstitial lung diseases: A systematic review and meta-analysis. Journal of Thoracic and Cardiovascular Surgery. 2015;149:1394.
  7. King CS, et al. Idiopathic pulmonary fibrosis: Effects and optimal management of comorbidities. The Lancet Respiratory Medicine. 2017;5:72.
  8. Canestaro WJ, et al. Drug treatment of idiopathic pulmonary fibrosis: Systematic review and network meta-analysis. Chest. 2016;149:756.
  9. Ueki N, et al. Impact of pretreatment interstitial lung disease on radiation pneumonitis and survival after stereotactic body radiation therapy for lung cancer. Journal of Thoracic Oncology. 2015;10:116.
  10. Sato T, et al. Long-term results and predictors of survival after surgical resection of patients with lung cancer and interstitial lung diseases. Journal of thoracic and cardiovascular surgery. 2015;149:64.
  11. King TE. Approach to the adult with interstitial lung disease: Clinical evaluation. https://www.uptodate.com/home. Accessed May 17, 2017.
  12. King TE. Treatment of idiopathic pulmonary fibrosis. https://www.uptodate.com/home. Accessed May 17, 2017.
  13. Celli BR. Pulmonary rehabilitation. https://www.uptodate.com/home. Accessed May 17, 2017.
  14. Bellini LM. Nutritional support in advanced lung disease. https://www.uptodate.com/home. Accessed May 17, 2017.
  15. Mayo Clinic. U.S. News & World Report. http://health.usnews.com/best-hospitals/area/mn/mayo-clinic-6610451/pulmonology. Accessed May 17, 2017.
  16. Warner KJ. Allscripts EPSi. Mayo Clinic, Rochester, Minn. March 30, 2017.
  17. AskMayoExpert. Interstitial lung disease. Rochester, Minn.: Mayo Foundation for Medical Education and Research; 2016.
  18. Moua T (expert opinion). Mayo Clinic, Rochester, Minn. May 19, 2017.
  19. King TE. Approach to the adult with interstitial lung disease: Diagnostic testing. https://www.uptodate.com/home. Accessed May 23, 2017.
  20. Morisset J, et al. Use of mycophenolate mofetil or azathioprine for the management of chronic hypersensitivity pneumonitis. Chest. 2017;151:619.
  21. Mathai SC, et al. Management of interstitial lung disease associated with connective tissue disease. BMJ. 2016;352:h6819.
  22. AskMayoExpert. Video-assisted thoracoscopic surgery. Rochester, Minn.: Mayo Foundation for Medical Education and Research; 2017.